First-line Advanced/Metastatic Squamous NSCLC: HARMONi-6 based Treatment Selection

Authored by Open Medicine, published on 2026-05-26 23:05:24.0

KEY PRINCIPLES

Perform molecular profiling before selecting therapy. Base treatment on PD-L1 TPS, disease burden, and patient factors. Use shared decision-making: efficacy goals, toxicity tolerance, patient preference, access/reimbursement. HARMONi-6 full ASCO 2026 data pending.
Advanced / Metastatic Squamous NSCLC

Stage IV or recurrent not amenable to curative therapy
- Comprehensive Molecular Profiling
  
  Recommend broad NGS (tissue or plasma) for all patients. Includes: EGFR, ALK, ROS1, BRAF, METex14 skipping, RET, NTRK, KRAS G12C, HER2, etc.
  - Actionable driver detected => Follow approved targeted therapy
    
    Yes → Use approved targeted therapy (Not part of HARMONi‑6 population)
  - No actionable driver detected => Tumor & Disease Factors / Patient Factors
    
    Tumor & Disease Factors: PD‑L1 TPS Disease burden (bulky disease, liver mets, extensive nodal disease) Pace of disease (rapidly progressive?) Symptom burden Patient Factors: ECOG performance status Organ function & comorbidities Autoimmune disease history Prior immune‑related toxicity Patient goals & preferences
    - Contraindication to chemoimmunotherapy?
      
      Active autoimmune disease Prior severe ICI toxicity / irAE Uncontrolled comorbidities Organ transplant
      - Non-IO option (platinum-doublet chemotherapy)
        
        If PD‑1/VEGF inhibitors are contraindicated or not appropriate: Platinum‑doublet chemotherapy (e.g., carboplatin + paclitaxel or nab‑paclitaxel) Maintenance: Observation or continuation of chemotherapy per clinical judgment
    - PD‑L1 TPS < 1% OR High Disease Burden / Need for Rapid Response (Any PD‑L1)
      - Intensified chemoimmunotherapy recommended
        
        Emerging preferred strategy: Ivonescimab + platinum-doublet chemotherapy (HARMONi-6)
        
        Ivonescimab + Platinum‑Doublet Chemotherapy (e.g., carboplatin + paclitaxel or nab‑paclitaxel) (HARMONi‑6 showed superior PFS vs tislelizumab + chemotherapy with favorable safety)
        
        Induction chemoimmunotherapy (typically 4–6 cycles)
        
        Ivonescimab or tislelizumab + platinum‑doublet chemotherapy per selected regimen
        
        Maintenance phase (continue assigned immunotherapy-based regimen until progression or unacceptable toxicity)
        
        Continue ivonescimab (HARMONi‑6 regimen) or tislelizumab as single‑agent maintenance until disease progression, unacceptable toxicity, up to 2 years (per product label and clinical judgment) or completion of planned duration.
    - PD‑L1 TPS 1–49% or Intermediate Disease Burden
      - Chemoimmunotherapy recommended; consider intensified regimen
        
        Emerging preferred strategy: Ivonescimab + platinum-doublet chemotherapy (HARMONi-6)
        
        Ivonescimab + Platinum‑Doublet Chemotherapy (e.g., carboplatin + paclitaxel or nab‑paclitaxel) Alternative (if not suitable for ivonescimab or per local access): tislelizumab + Platinum‑Doublet Chemotherapy Decision should incorporate patient factors and shared decision‑making
        
        Induction chemoimmunotherapy (typically 4–6 cycles)
        
        Ivonescimab or tislelizumab + platinum‑doublet chemotherapy per selected regimen
        
        Maintenance phase (continue assigned immunotherapy-based regimen until progression or unacceptable toxicity)
        
        Continue ivonescimab (HARMONi‑6 regimen) or tislelizumab as single‑agent maintenance until disease progression, unacceptable toxicity, up to 2 years (per product label and clinical judgment) or completion of planned duration.
    - PD‑L1 TPS ≥ 50% and Lower Disease Burden
      - Chemoimmunotherapy remains standard (IO monotherapy is an option in select asymptomatic, low‑burden cases)
        
        Emerging preferred strategy: Ivonescimab + platinum-doublet chemotherapy (HARMONi-6)
        
        Ivonescimab + Platinum‑Doublet Chemotherapy (e.g., carboplatin + paclitaxel or nab‑paclitaxel) Alternative: Tislelizumab + Platinum‑Doublet Chemotherapy IO monotherapy (e.g., pembrolizumab) may be considered only in carefully selected patients with low tumor burden, minimal symptoms, and high likelihood of durable response
        
        Induction chemoimmunotherapy (typically 4–6 cycles)
        
        Ivonescimab or tislelizumab + platinum‑doublet chemotherapy per selected regimen
        
        Maintenance phase (continue assigned immunotherapy-based regimen until progression or unacceptable toxicity)
        
        Continue ivonescimab (HARMONi‑6 regimen) or tislelizumab as single‑agent maintenance until disease progression, unacceptable toxicity, up to 2 years (per product label and clinical judgment) or completion of planned duration.
HOW HARMONi‑6 INFORMS PRACTICE

Population: untreated advanced squamous NSCLC without actionable drivers HARMONi-6: ivonescimab + chemo improved PFS vs tislelizumab + chemo Pembrolizumab-chemo remains a major global standard. Ivonescimab + chemo may become an emerging new standard Individualize based on disease biology and patient factors

tos privacy Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial